Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Callender, A. Alexis, L. Gold, M. Lebwohl, A. Paller, S. Desai, H. Tan, W. Ports, M. Zielinski, A. Tallman (2019)
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsAmerican Journal of Clinical Dermatology, 20
(Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel, Switzerland). 2019;6(12). )
Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel, Switzerland). 2019;6(12).Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel, Switzerland). 2019;6(12). , Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel, Switzerland). 2019;6(12).
H. Murota, Y. Koike, Hitomi Morisaki, Mai Matsumoto, M. Takenaka (2021)
Exacerbating factors and disease burden in patients with atopic dermatitis.Allergology international : official journal of the Japanese Society of Allergology
(Protopic 0.03% ointment. Summary of product characteristics. Astellas Ireland Co. Ltd.: Kerry, Ireland; 2022)
Protopic 0.03% ointment. Summary of product characteristics. Astellas Ireland Co. Ltd.: Kerry, Ireland; 2022Protopic 0.03% ointment. Summary of product characteristics. Astellas Ireland Co. Ltd.: Kerry, Ireland; 2022, Protopic 0.03% ointment. Summary of product characteristics. Astellas Ireland Co. Ltd.: Kerry, Ireland; 2022
(StaquisTM (crisaborole). Prescribing information. Pfizer Australia Pty Ltd: Sydney, Australia; 2019.)
StaquisTM (crisaborole). Prescribing information. Pfizer Australia Pty Ltd: Sydney, Australia; 2019.StaquisTM (crisaborole). Prescribing information. Pfizer Australia Pty Ltd: Sydney, Australia; 2019., StaquisTM (crisaborole). Prescribing information. Pfizer Australia Pty Ltd: Sydney, Australia; 2019.
C. Na, Janice Chung, E. Simpson (2019)
Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their FamiliesChildren, 6
J. Berth‐Jones, R. Damstra, S. Golsch, J. Livden, Oliver Hooteghem, F. Allegra, C. Parker (2003)
Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group studyBMJ : British Medical Journal, 326
(Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–9 e5.)
Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–9 e5.Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–9 e5., Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–9 e5.
(Staquis™ (crisaborole ointment, for topical use). Prescribing information. Pfizer Inc.: New York; 2020.)
Staquis™ (crisaborole ointment, for topical use). Prescribing information. Pfizer Inc.: New York; 2020.Staquis™ (crisaborole ointment, for topical use). Prescribing information. Pfizer Inc.: New York; 2020., Staquis™ (crisaborole ointment, for topical use). Prescribing information. Pfizer Inc.: New York; 2020.
G. Girolomoni, Valentina Busà (2022)
Flare management in atopic dermatitis: from definition to treatmentTherapeutic Advances in Chronic Disease, 13
(Preucrisa (crisaborole ointment, 2 % for topical use phosphodiesterase-4 (PDE-4) inhibitor). Prescribing information. Pfizer Canada Inc.: Kirkland, Quebec; 2018.)
Preucrisa (crisaborole ointment, 2 % for topical use phosphodiesterase-4 (PDE-4) inhibitor). Prescribing information. Pfizer Canada Inc.: Kirkland, Quebec; 2018.Preucrisa (crisaborole ointment, 2 % for topical use phosphodiesterase-4 (PDE-4) inhibitor). Prescribing information. Pfizer Canada Inc.: Kirkland, Quebec; 2018., Preucrisa (crisaborole ointment, 2 % for topical use phosphodiesterase-4 (PDE-4) inhibitor). Prescribing information. Pfizer Canada Inc.: Kirkland, Quebec; 2018.
T. Zuberbier, S. Orlow, A. Paller, A. Taïeb, R. Allen, J. Hernanz‐Hermosa, J. Ocampo-Candiani, M. Cox, Joanne Langeraar, J. Simon (2006)
Patient perspectives on the management of atopic dermatitis.The Journal of allergy and clinical immunology, 118 1
A. Massarano, S. Hollis, J. Devlin, T. David (1993)
Growth in atopic eczema.Archives of Disease in Childhood, 68
Emma Axon, J. Chalmers, M. Santer, M. Ridd, S. Lawton, S. Langan, D. Grindlay, I. Muller, A. Roberts, A. Ahmed, H. Williams, K. Thomas (2021)
Safety of topical corticosteroids in atopic eczema: an umbrella reviewBMJ Open, 11
M. Boguniewicz, L. Fonacier, E. Guttman‐Yassky, P. Ong, J. Silverberg, J. Farrar (2018)
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 120 1
(2018)
Preucrisa (crisaborole ointment, 2 % for topical use phosphodiesterase-4 (PDE-4) inhibitor). Prescribing information
K. Yamamoto-Hanada, Yuichi Suzuki, Limin Yang, M. Saito-Abe, M. Sato, H. Mezawa, Minaho Nishizato, N. Kato, Yoshiya Ito, K. Hashimoto, Y. Ohya (2021)
Persistent eczema leads to both impaired growth and food allergy: JECS birth cohortPLoS ONE, 16
A. Paller, W. Tom, M. Lebwohl, R. Blumenthal, M. Boguniewicz, R. Call, L. Eichenfield, D. Forsha, W. Rees, E. Simpson, M. Spellman, L. Gold, A. Zaenglein, Matilda Hughes, L. Zane, A. Hebert (2016)
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.Journal of the American Academy of Dermatology, 75 3
Andreas Wollenberg, T. Bieber (2009)
Proactive therapy of atopic dermatitis – an emerging conceptAllergy, 64
Protopic 0.03% ointment. Summary of product characteristics
T. Luger, A. Hebert, A. Zaenglein, J. Silverberg, H. Tan, W. Ports, M. Zielinski (2022)
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 YearsPaediatric Drugs, 24
M. Lam, J. Zhu, Mina Tadrous, A. Drucker (2021)
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.JAMA dermatology
L. Eichenfield, W. Tom, T. Berger, A. Krol, A. Paller, K. Schwarzenberger, J. Bergman, S. Chamlin, D. Cohen, K. Cooper, K. Cordoro, D. Davis, S. Feldman, J. Hanifin, D. Margolis, R. Silverman, E. Simpson, H. Williams, C. Elmets, J. Block, C. Harrod, Wendy Begolka, R. Sidbury (2014)
Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.Journal of the American Academy of Dermatology, 71 1
M. Asgari, Ai‐Lin Tsai, Lyndsay Avalos, Monica Sokil, C. Quesenberry (2020)
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.JAMA dermatology
B. Kaufman, E. Guttman‐Yassky, A. Alexis (2018)
Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatmentExperimental Dermatology, 27
(Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.)
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32., Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Valle, S. Barbarot, T. Bieber, H. Brough, P. Pinton, S. Christen-Zäch, M. Deleuran, M. Dittmann, C. Dressler, A. Fink-Wagner, N. Fosse, K. Gáspár, L. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, C. Mortz, A. Nast, U. Nygaard, M. Redding, E. Rehbinder, J. Ring, M. Rossi, E. Serra-Baldrich, D. Simon, Z. Szalai, J. Szepietowski, A. Torrelo, T. Werfel, C. Flohr (2022)
European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populationsJournal of the European Academy of Dermatology and Venereology, 36
S. Noda, M. Suárez-Fariñas, B. Ungar, S. Kim, C. Strong, Hui Xu, Xiangyu Peng, Y. Estrada, Saeko Nakajima, T. Honda, J. Shin, H. Lee, J. Krueger, K. Lee, K. Kabashima, E. Guttman‐Yassky (2015)
The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization.The Journal of allergy and clinical immunology, 136 5
(2020)
Staquis™ (crisaborole ointment, for topical use)
E. Bacci, A. Rentz, J. Correll, E. Pierce, A. DeLozier, M. Rueda, W. Begolka, Lisa Butler (2021)
Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis.Journal of drugs in dermatology : JDD, 20 11
A. Wollenberg, S. Christen-Zäch, Alain Taïeb, Carle Paul, J. Thyssen, M. Bruin-Weller, C. Vestergaard, J. Seneschal, T. Werfel, M. Cork, B. Kunz, R. Fölster-Holst, M. Trzeciak, U. Darsow, Z. Szalai, M. Deleuran, L. Kobyletzki, L. Kobyletzki, S. Barbarot, A. Heratizadeh, U. Gieler, D. Hijnen, S. Weidinger, L. Raeve, Å. Svensson, D. Simon, J. Stalder, J. Ring (2020)
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and childrenJournal of the European Academy of Dermatology and Venereology, 34
L. McDowell, B. Olin (2019)
Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic DermatitisJournal of Pharmacy Technology, 35
L. Eichenfield, R. Call, D. Forsha, J. Fowler, A. Hebert, M. Spellman, L. Gold, Merrie Syoc, L. Zane, E. Tschen (2017)
Long‐term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisJournal of the American Academy of Dermatology, 77
J. Hanifin, G. Rajka (1980)
Diagnostic Features of Atopic DermatitisActa Dermato-Venereologica
T. Luger, M. Augustin, J. Lambert, C. Paul, C. Pincelli, A. Torrelo, C. Vestergaard, U. Wahn, T. Werfel (2020)
Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimusPediatric Allergy and Immunology, 32
Gil Yosipovitch, M. Reaney, V. Mastey, L. Eckert, A. Abbe, Lauren Nelson, M. Clark, N. Williams, Zhen Chen, M. Ardeleanu, B. Akinlade, N. Graham, G. Pirozzi, H. Staudinger, S. Plaum, Allen Radin, A. Gadkari (2019)
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis†The British Journal of Dermatology, 181
A. Wollenberg, S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran, A. Fink-Wagner, U. Gieler, G. Girolomoni, S. Lau, A. Muraro, M. Czarnecka-Operacz, T. Schäfer, P. Schmid‐Grendelmeier, D. Simon, Z. Szalai, J. Szepietowski, A. Taïeb, A. Torrelo, T. Werfel, Johannes Ring (2018)
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IJournal of the European Academy of Dermatology and Venereology, 32
Brian Johnson, Abigail Franco, L. Beck, J. Prezzano (2019)
Treatment-resistant atopic dermatitis: challenges and solutionsClinical, Cosmetic and Investigational Dermatology, 12
BackgroundTopical treatments for atopic dermatitis (AD) used reactively often fail to achieve lasting disease control; many of these therapies are associated with safety concerns that limit long-term use. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD that has potential as a long-term maintenance therapy.ObjectiveThe aim was to evaluate the long-term efficacy and safety of crisaborole once daily (QD) compared to vehicle QD as a maintenance therapy to reduce the incidence of flares in patients with AD who previously responded to crisaborole twice daily (BID).MethodsCrisADe CONTROL was a randomized, double-blind, vehicle-controlled, 52-week, phase III study of patients aged ≥ 3 months with mild-to-moderate AD involving ≥ 5% treatable body surface area. Eligible patients received crisaborole BID during an open-label run-in period of up to 8 weeks. Responders were randomly assigned in the double-blind maintenance period to receive either crisaborole QD or vehicle QD. Responders were defined as patients who achieved Investigator’s Static Global Assessment (ISGA) success (ISGA score of 0 [clear] or 1 [almost clear] with a ≥ 2-grade improvement) and ≥ 50% improvement in Eczema Area and Severity Index total score (EASI-50) from baseline. Patients who experienced a flare (ISGA score ≥ 2) during the double-blind maintenance period switched to crisaborole BID for up to 12 weeks. During this period, patients were assessed every 4 weeks; if the flare resolved (ISGA score ≤ 1), patients resumed their assigned treatment. The primary endpoint was flare-free maintenance until onset of the first flare. Key secondary endpoints were number of flare-free days, number of flares, and maintenance of pruritus response until onset of the first flare. The incidence of treatment-emergent adverse events was also analyzed.ResultsOverall, 497 patients entered the open-label run-in period with crisaborole BID, of which 270 patients were randomized into the 52-week double-blind maintenance period of the study. Of the 270 patients, 135 were randomly assigned to the crisaborole QD group and 135 were randomly assigned to the vehicle QD group. Median time of flare-free maintenance was longer for patients who received crisaborole versus vehicle (111 vs 30 days, respectively; p = 0.0034). The mean number of flare-free days was higher for patients who received crisaborole versus vehicle (234.0 vs 199.4 days, respectively; p = 0.0346). The mean number of flares was lower for patients who received crisaborole versus vehicle (0.95 vs 1.36, respectively; p = 0.0042). No clear trend was observed in maintenance of pruritus response between crisaborole- and vehicle-treated patients. Crisaborole was well tolerated, with no new or unexpected safety findings when used as maintenance treatment.ConclusionsCrisaborole QD was effective and well tolerated for long-term maintenance treatment and flare reduction in adult and pediatric patients with mild-to-moderate AD.Trial RegistrationClinicalTrials.gov, NCT04040192, 31 July 2019.
American Journal of Clinical Dermatology – Springer Journals
Published: Jul 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.